Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.210
-0.010 (-0.82%)
At close: Apr 2, 2026, 4:00 PM EDT
1.240
+0.030 (2.48%)
After-hours: Apr 2, 2026, 4:42 PM EDT

Silexion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
4.496.760.970.63
Research & Development
7.145.823.713.23
Total Operating Expenses
11.6312.574.683.86
Operating Income
-11.63-12.57-4.68-3.86
Total Non-Operating Income (Expense)
-0.28-3.94-0.40.4
Pretax Income
-11.91-16.51-5.08-3.46
Provision for Income Taxes
00.010.030.02
Net Income
-11.91-16.44-4.94-3.22
Minority Interest in Earnings
--0.08-0.17-0.27
Net Income to Common
-11.91-16.44-4.94-3.22
Shares Outstanding (Basic)
1000
Shares Outstanding (Diluted)
1000
Shares Change (YoY)
3093.26%458.98%0.04%-
EPS (Basic)
8.96394.94663.45-431.85
EPS (Diluted)
8.96394.94663.45-431.85
EPS Growth
-97.73%-40.47%--
Shares Outstanding
3.130.120.010.01
Free Cash Flow
-10.83-8.42-4.54-3.38
Free Cash Flow Per Share
-8.14-202.19-609.66-453.28
EBITDA
-11.62-12.55-4.64-3.8
EBIT
-11.63-12.57-4.68-3.86
Effective Tax Rate
-0.03%-0.06%-0.63%-0.69%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q